natgillin/translations-raw huggingface dataset:
two hub-carrying groups (7), each of which is slidably guided along a corresponding said shoulder (4) in said vertical extension direction (Y), and is susceptible to be mechanically engaged with one end of said reel (5); characterized in that it comprises: 
- < dvije skupine nosača glavčine (7), od kojih se svaka klizno vodi uzduž odgovarajućeg izbočenog oslonca (4) u spomenutom vertikalnom smjeru protezanja (Y), 1 sa sklonošću da bude mehanički zahvaćena s jednim krajem navedenog kalema (5); naznačen time, da obuhvaća sljedeće:
4 mL of the previously prepared nitrating mixture is added dropwise over 15 minutes. 
Tijekom 15 minuta doda se kap po kap 4 mL prethodno pripravljene mješavine za nitriranje.
propagation of a fungus and production of enzymes by the fungus, wherein a part of the enzymatically hydrolysed lignocellulosic material and a part of the pretreated lignocellulosic material is used in the propagation of the fungus and/or the production of enzymes by the fungus and wherein the enzymes produced by the fungus are used in the enzymatic hydrolysis. 
razmnožavanje gljivice i proizvodnje enzima pomoću gljivice, pri čemu se dio enzimski hidroliziranog lignoceluloznog materijala dio prethodno obrađenog lignoceluloznog materijala koristi u razmnožavanju gljivice i/ili proizvodnji enzima pomoću gljivice i pri čemu se enzimi proizvedeni s gljivicom koriste u enzimskoj hidrolizi.
Formulation for anticorrosion paints and coatings according to claim 6, wherein said nanoparticles consist of montmorillonite. 
sastav za antokorozivne slike i premaze sukladno zahtjevu 6, naznačeno time da se sporemute nanočestice sastoje od montmorilonita
An isolated anti-IL-6 antibody comprising a VL or VH polypeptide sequence having at least 90% or greater homology to any one of the polypeptide sequences recited in clause 83. 
HR P20191013 T1 protutijelo sadrži VL lanac 1 Vy lanac, redom, koji ima aminokiselinske sljedove koji k tome imaju najmanje 90% ili više homologije.
In most embodiments of the methods of producing a reagent for tissue samples, the method comprises providing at least one chaotrope, providing at least one kosmotrope, providing a chelator, providing a buffer, providing an apoptosis substrate, providing a metabolic modulator, and mixing the chaotrope, kosmotrope, chelator, buffer, apoptosis substrate, and the metabolic modulator in such a manner as to enable the gene expression analysis of the tissue sample. 
HR P20181352 T1 PATENTNI ZAHTJEVI Reagens za kirurški odstranjeni uzorak tumorskog tkiva radi omogućavanja analize genetske ekspresije, te reagens sadrži slijedeće komponente: barem jedan kaotrop; barem jedan kozmotrop; kelator; pufer; supstrat apoptoze, i metabolički modulator; pri čemu supstrat apoptoze je leptin; i pri čemu barem jedan kozmotrop je a,a-trehaloza.
an anisotropic blurring device configured to generate an anisotropic blur image by applying an anisotropic smoothing filter to the band image, the anisotropic smoothing filter depending on the direction of the gradient; 
uređaj za neizotropno zamagljenje (15) koji ima konfiguraciju za stvaranje neizotropno zamagljene slike (P2) pomoću nanošenja neizotropnog filtera za omekšavanje šuma na sliku na traci (a, B, Y), gdje neizotropni filter za omekšavanje šuma ovisi o smjeru gradijenta (m);
A process for the preparation of compound (II) comprising 
Spoj formule (2c-2B) naznačen time što se koristi za pripremu spoja (X).
A fusion peptide according to any of preceding claim 1 to 17, wherein at least one of the amino acids is derivatized by a lipyl or carbohydrate group. 
Fuzijski peptid prema patentnom zahtjevu 14, naznačen time da je najmanje jedna od aminokiselina derivirana lipidnom ili ugljikohidratnom skupinom.
The first antigen binding protein according to claim 2, wherein said second antigen binding protein is an antibody comprising a variable heavy chain (VH) and a variable light chain (VL), wherein VH and VL comprise the amino acid sequences set forth below: 
2. - Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što protutijelo ima varijabilni teški lanac (VH) i varijabilni laki lanac (VL), gdje VH i VL imaju aminokiselinske sljedove iznijete niže: (a) (b)
After evaporation of the solvents under vacuum, the residue was purified by chromatography on silica gel (eluant: 2% 7N methanolic ammonia in dichloromethane) to give the title compound as a white solid (100 mg, 72%). 
Nakon otparavanja otapala pod vakuumom, talog je pročišćen kromatografijom na silika-gelu (eluens: 2% 7N metanolni amonijak u diklormetanu) čime je dobiven spoj iz naslova u obliku bijele krutine (100 mg,
A composition comprising as an active principle a compound consisting of an antibody, or one of its functional fragments or derivatives, as claimed in one of claims 3-9, 11, 12, 14, 15, 17 18, 20, 21 and 22, or obtained by the process of claim 26, or produced by the hybridoma according to claims 10, 12, 16 and 19. 
Pripravak koji kao aktivni sastojak sadrži spoj koji se sastoji od antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met kao što je prijavljeno u jednom od patentnih zahtjeva 1, 2 te 4 - 8 ili je dobiven metodom iz patentnog zahtjeva 12, ili je dobiven pomoću hibridoma prema patentnom zahtjevu 3.
Figure 1: Total emission of formaldehyde by foams just prepared (the diluting air was fed in at a flow rate of 1.5 lt/ minute, at 20°C). 
Slika 1. Cjelokupna emisija iz upravo pripremljenih pjena (zrak za razrjeđivanje šiljali smo u količini od 1,5 1/minutu kod 20*C).
A B7-H1 blocking antibody for use in a method of treating cancer in combination with a radiation treatment, wherein the B7-H1 blocking antibody is administered following the radiation treatment, and wherein said B7-H1 blocking antibody is an anti-B7-H1 antibody. 
PATENTNI ZAHTJEVI Antitijelo koje blokira B7-H1 za uporabu u postupku liječenja raka u kombinaciji s liječenjem radijacijom, pri čemu je antitijelo koje blokira B7-H1 primijenjeno nakon liječenja radijacijom, 1 pri čemu navedeno antitijelo koje blokira B7-H1 je anti-B7-H1 antitijelo.
a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain fragment of the Fab' fragment according to Claim 1 and a polynucleotide comprising sequence that encodes the light chain of the Fab' fragment; and 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab’ fragmenta u skladu s patentnim zahtjevom 2 i polinukleotid koji sadrži slijed koji kodira laki lanac Fab’ fragmenta u skladu s patentnim zahtjevom 2; i
The lack of activity at the VAT transporter means that tetrabenazine has less peripheral activity than reserpine and consequently does not produce VMAT1-related side effects such as hypotension. 
Nedostatak djelovanja na VMATI transporter znači da tetrabenazin ima manje periferno djelovanje od rezerpina i kao posljedicu toga da ne izaziva nuz-djelovanja povezana s VMATI, poput hipotenzije.
A liquid long acting injectable formulation for use according to claim 10, wherein the endoparasite is a helminth selected from the group consisting of Ostertagia, Haemonchus, and mixtures thereof wherein said helminth is resistant to macrolide antibiotics when not administered by the method of claim 10. 
Tekuća injektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da endoparazit je helmint odabran iz skupine koju čine: Ostertagia, Haemonchus i njihove kombinacije, pri čemu je helmint otporan na makrolidne antibiotike ako nisu primjenjeni u skladu sa zahtjevom 8.
A pharmaceutical composition comprising the antibody of any one of claims 1 - 4, or an antigen binding fragment thereof, the nucleic acid of any one of claim 6, the vector of claim 7, or the cell of claim 8, and a pharmaceutically acceptable diluent or carrier. 
Farmaceutski pripravak naznačen time što sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1-7, ili njegov ulomak koji veže antigen, nukleinsku kiselinu prema zahtjevu 8 ili 9, vektor prema zahtjevu 10, ili stanicu prema zahtjevu 11, te farmaceutski prihvatljivo sredstvo za razrjeđivanje 1li nosač.
The composition for use according to claim 1, wherein said skin disorder is skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je navedeni kožni poremećaj senzibilizacija kože, iritacija kože, kožni osip, kontaktni dermatitis ili alergijska kontaktna senzibilizacija kože.
Wheat fibres included in the second, third and fourth embodiments also have anti-caking properties. 
Pšenična vlakna uključena u treću i četvrtu varijantu također djeluju protuzgrudnjavajuće.
The outer tube is rotational relative to the remaining endoscope parts. 
Ova vanjska cijev može rotirati u odnosu na preostale dijelove endoskopa.
Step D relates to the coupling of a 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine, C, prepared in Step C with an amino acid, amino acid ester, or amino acid amide. 
D) reakciju 5-aril ili 5-heteroaril-3-hidroksi-2-karboksipiridina formiranog u koraku (C) sa spojem formule: i 2N COH e
The method of claim 2 wherein at least one of the additional compounds having anti-HCV activity is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5′-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
The compound of any one of claims 1-3 wherein at least one of E1a and E1b is -N(H)C(=O)OMe. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E"" je -N(H)C(=0)0Me.
The composition for use of claim 1, wherein the gastroesophageal reflux disease (GERD) is refractory to an acid inhibitor. 
Oralni farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1-5, gdje je upala jednjaka povezana s Barrettovim jednjakom, gastroezofagealnom refluksnom bolesti (GERD), neerozivnom refluksnom bolesti (NERD), ili erozivnim ezofagitisom.
and R5 for each occurrence is, independently, H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteraralkyl; n is an integer selected from 0-4; p is 0, 1, or 2; and 
Ru, i Rs za svaku pojavu je, nezavisno, H, opcijski supstituiran alkil, opcijski supstituiran alkenil, opcijski supstituiran alkinil, opcijski supstituiran cikloalkil, opcijski supstituiran cikloalkenil, opcijski supstituiran heterociklil, opcijski supstituiran aril, opcijski supstituiran heteroaril, opcijski supstituiran aralkil, ili opcijski supstituiran heteraralkil; n je cijeli broj odabran od 0-4; pje0,1l,ili2;i uje 0, 1, ili 2.
H-indazole-3-carboxamide for the use according to claim 12, wherein said neurodegenerative diseases are selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, and spinal neurodegenerative disorders. 
H-indazol-3-karboksamid za uporabu prema zahtjevu 12, naznačen time, da su navedene neurodegenerativne bolesti odabrane iz skupine koju čine Parkinsonova bolest, Alzheimerova bolest, Hungtingtonova bolest i spinalni neurođegenerativni poremećaji.
The system of claim 9, further comprising a CGI compositor and the optical navigation system being configured to provide camera position data for the CGI compositor. 
Sustav u skladu s patentnim zahtjevom 12 ili patentnim zahtjevom 13, naznačen time što dodatno sadrži CGI kompozitor, te što je sustav za optičku navigaciju (10) prilagođen za davanje podataka o položaju kamere za CGI kompozitor.
The method comprises the steps of: cutting a hole in the abdominal wall of the patient, dissecting an area around the stomach, placing the device in contact with the stomach, and fixating, direct or indirect, through invagination of the stomach wall the, device to the stomach wall such that the device can stretch a portion of the stomach wall. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni uređaj ima najmanje dva upravljiva uređaja za rastezanje (410b), prilagođena za rastezanje najmanje dva različita dijela stijenke želuca, gdje je uređaj prilagođen za postoperativno i nemvazivno upravljanje.
This indicates that under these conditions the RME is not incorporated primarily through oxidative reactions as described in EP 685543, DE 3803141, DE 3701410, etc. 
To polazuje da pod tim uvjetima RME nije ugrađen primarno reakcijama oksidacije, kako je opisano u EP 685543, DE 3803141, DE 3701410, itd.
In one embodiment, the invention is directed to compounds of formula (I) wherein 
PATENTNI ZAHTJEVI Kombinacija, naznačena time što sadrži spoj formule (I):
The modified virus of claim 1, wherein the virus is a poliovirus, rhinovirus, influenza virus, severe acute respiratory syndrome (SARS) coronavirus, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), infectious bronchitis virus, Ebolavirus, Marburg virus, dengue fever virus, West Nile disease virus, Epstein-Barr virus (EBV), or yellow fever virus. 
Oslabljeni virus prema zahtjevu 1., naznačen time što je virus poliovirus, rinovirus, virus influence, teški akutni respiratorni sindrom (SARS), koronavirus, virus humane imunodeficijencije (HIV), virus hepatitisa € (HCV), virus infektivnog bronhitisa, virus Ebole, virus Marburg, virus denga groznice, virus groznice Zapadnog Nila, Epstein-Barr virus (EBV), ili virus žute groznice.
After evaporation of the solvents under vacuum, the residue was triturated in water. 
Nakon otparavanja otapala pod vakuumom, talog je trituriran u vodi.
Embodiment 12 The process of any of embodiments 1 to 11, wherein the compound of formula IIa-1 is a compound of formula IIa; the compound of formula II-1 is a compound of formula I; and the compound of formula I is a compound of formula I′. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se navedeni spoj Formule IV dobiva uklanjanjem zaštite s azetidinilnog prstena u spoju formule V, gdje je PG zaštitna skupina za amino, kako bi se dobilo spoj formule IV:
represents hydrogen; 
R> predstavlja vodik;
This is valid for all aforementioned reactive diluents based on fatty acid derivatives with reactive groups present on the carbon chain, but not for the present invention since all reactive diluents according to the invention contain a carboxyl or acyl functional group. 
To vrijedi za sva gore spomenuta reaktivna sredstva za razrjeđivanje na temelju derivata masnih kiselina s reaktivnim skupinama prisutnim na ugljikovom lancu, ali ne i za predloženi izum, jer sva reaktivna sredstvo za razrjeđivanje prema izumu sadrže karboksilnu ili kiselinsku funkcionalnu skupinu.
The composition, method or kit of claim 6, wherein said dsRNA duplex has a length of from 8 to 10 bp. 
Sastav, postupak ili garnitura prema zahtjevu 6, naznačen/a time, da navedena dsRNK-dupleks ima duljinu od & bp do 10 bp.
The invention also relates to a method of utilizing the expanded adult stem cells obtained according to the expansion method described above for the preparation of a medication for treating lesions of mammals. The treatable lesions include, without limitation, cutaneous lesions, lesions to tendons, lesions to ligaments, bone lesions, lesions to the mucous membranes, and fractures. The present invention also relates to a method of utilizing the expanded adult stem cells obtained according to the method described above for the preparation of a medication for treating neurological or neurodegenerative pathologies in mammals, including, without limitation, Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, paresis of the limbs; acute or chronic inflammatory pathologies such as laminitis, periostitis, gastritis, arthrosis, inflammations caused by viral, bacterial, parasite, and/or mycotic agents; and dilatation-torsion of the stomach. 
Ficoll gradijentu. Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 90-250x10* stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za intravenoznu injekciju, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
An eighth example concerns a recipe for "butter cookies" in which the following ingredients are used: 
U osmom primjeru iznosi se recept za Â«kekse s maslacem» za koje su potrebni sljedeći sastojci: -
connecting the space which is enclosed by the cover layer (10) and the mould to a discharge (20), 
- < povezivanje prostora koji je zatvoren pokrovom (10) 1 kalupa s ispustom (20),
A beam-like block of wood 12 having a height of 300 mm was provided according to the invention, whereby, accordingly, 6 of such oak boards 10 were glued with each other. 
Blok od drva koji ima oblik grede 12 i koji ima visinu od 300 mm, pri čemu, u skladu s tim, 6 takvih hrastovih ploča 10 je bilo zalijepljeno jedna s drugom.
to give a compound of formula (XIV): 
š pri čemu nastaje spoj formule (XIV): 8
A compound according to claim 3, having the structure wherein m is not 0, preferably where Z is CO2Q, Q is hydrogen, and m is 4. 
CO gdje m nije 0. Tvar u skladu s patentnim zahtjevom 5, pri čemu je Z jednak CO2Q, Q je vodik, a mje 4.
The method of embodiment 51, wherein the pluripotent cell is a non-human embryonic stem (ES) cell. 
Postupak sukladno patentnom zahtjevu 4, naznačen time, da je ta stanica mišja embrijska matična (ES) stanica.
Disclosed are those compounds wherein R4 is phenyl substituted at the 4-position with hydroxy, C1-3alkylaminocarbonyl, or aminocarbonyl, and substituted at the 2- and 6- positions with methyl substituents. 
Spoj prema zahtjevu 1 maznačen time da R' je fenil supstituiran na 4-poziciji sa hidroksi, C,salkilaminokarbonilom ili aminokarbonilom i supstituiran na 2- poziciji i 6-poziciji sa metil supstituentima.
The siRNA according to any one of claims 1 to 3, wherein 1 to 10 consecutive nucleotides from the 5' terminus of the antisense strand of the siRNA are converted into DNA. 
siRNA u skladu sa zahtjevom 1 ili 2, naznačena time, da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
A compound of formula (II), a salt, or a stereoisomer thereof. wherein R1 is hydrogen; 
Spoj formule (II), sol, ili a njegov stereoizomer [image], naznačen time što: je vodik;
The protruding portion 20 can engage into the recess 23 . 
Stršeći dio 20 zahvatiti u udubljenje 23.
The residue is loaded on a pre-packed Isolute™ silica column and eluted using a gradient eluent from 100% CH2Cl2 to 5% methanol in CH2Cl2 to afford the title compound; MH+=374. 
Ostatak se stavi na predpakirani Isolute " stupac silika gela i ispere s gradijentom cluenta od 100% CHLCI, do 5% metanola u CH,C1,, čime se dobije naslovni spoj; MH"
at least 0.01 % by weight of the API; 
najmanje 0,01 % masenog udjela API-ja;
A method for the treatment of a disease related to 5-HT6 receptor where said disease is schizophrenia, comprising the step of administering to a patient in need thereof an effective amount of a compound according to claim 3 . 
Spoj formule (ID prema patentnom zahtjevu 3, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT4 receptorima.
This may be carried out for instance so that the surfaces of the portion 10 inserted between the sheets 6 and 7 of the attachment portion 2 are provided with layers of adhesive agent before placing the flexible and bending resistant sheet forming the attachment portion 2 in position between the sheets 6 and 7 to be laminated. 
To se može izvesti, na primjer, tako da se površine predjela 10 predjela za povezivanje 2, koji je umetnut između listova 6 i 7, snabdiju sa slojevima ljepljivog sredstva prije stavljanja lista u položaj između listova 6 i 7, koji list je otporan na pregibanje i na savijanje i koji čini predio za povezivanje 2, da tamo bude pričvršćen kao sloj.
Use of the radioactive metal-labeled anti-P-cadherin antibody as recited in any one of claims 5 or 6 for producing a cancer therapeutic agent, or as recited in claim 7 for producing a cancer diagnostic agent. 
Upotreba anti-P-kadherin antitijela obilježenog radioaktivnim metalom, kako je navedeno u skladu s bilo kojim od patentnih zahtjeva 5 ili 6, naznačena time, da služi za proizvodnju terapijskog sredstva protiv raka ili u skladu s patentnim zahtjevom 7 za pripravu sredstva za dijagnozu raka.
The coated tablet core according to claim 32 wherein the tablet core comprises 0.1-1% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 60-80% metformin hydrochloride; 1-10% hydroxypropyl cellulose; 2-25% microcrystalline cellulose; 4-10% sodium starch glycolate or 3-10% hydroxypropyl cellulose, low substituted; and 0.25-2.5% magnesium stearate; 
Jezgra obložene tablete prema zahtjevu 32 naznačena time što (1) jezgra tablete sadrži 0.1-1% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 60-80% metformin hidroklorida; 1-10% hidroksipropil celuloze; 2-25% mikrokristalne celuloze; 4-10% natrijevog škrob glikolata ili 3-10% hidroksipropil celuloze, nisko supstituirane; i 0.25-2.5% magnezijevog stearata;
said time value (TV) is transmitted to said concentrator (C), and 
- navedena vremenska funkcija (TV) se prenosi u sabirnik (C), i
the offset residual decoding means decodes each offset residual in association with an offset type, which is determined for each unit area, and an offset class, which is determined for each pixel; and 
dekodiranje offseta koji je ograničen na raspon offset vrijednosti; i dodavanje offset vrijednosti piksela za svaki piksel jedinične površine deblokirane dekodirane slike.
The pharmaceutical composition for use according to claim 17, wherein the antibody or functional fragment thereof which inhibits osteoclast formation and/or osteoclastic bone resorption is a monoclonal antibody or a functional fragment thereof in accordance with any one of claims 1 to 15. 
Farmaceutski pripravak za uporabu prema zahtjevu 17 u kojem je antitijelo ili njegov funkcionalni fragment, koji inhibiraju razvoj osteoklasta i/ili osteoklastnu resorpciju kostiju, monoklonsko antitijelo ili njegov funkcionalni fragment sukladno bilo kojem od zahtjeva 1-15.
wherein a, b and c define the length of the sides of the unit cells; a, B and Y define the relative angles of the cell sides; V defines the volume of the cell; 
[image] gdje a, b i c definiraju duljinu strana jediničnih ćelija; a, B i Y definiraju relativne kuteve strana ćelije; V definira volumen ćelije;
is selected from 
R' je Hili je odabran između
A pharmaceutical composition comprising the compound according to any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 14, i terapeutski inertan nosač.
Hungarian Patent Application No. 
Broj europske prijave patenta: